Compare QLYS & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QLYS | BLLN |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2012 | N/A |
| Metric | QLYS | BLLN |
|---|---|---|
| Price | $90.38 | $70.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $136.00 | $129.57 |
| AVG Volume (30 Days) | ★ 538.1K | 297.5K |
| Earning Date | 05-05-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.99 | N/A |
| EPS | ★ 5.44 | N/A |
| Revenue | ★ $321,607,000.00 | N/A |
| Revenue This Year | $9.96 | $45.89 |
| Revenue Next Year | $7.15 | $30.17 |
| P/E Ratio | $16.52 | ★ N/A |
| Revenue Growth | ★ 15.32 | N/A |
| 52 Week Low | $85.14 | $61.96 |
| 52 Week High | $155.47 | $138.70 |
| Indicator | QLYS | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 33.69 | 44.27 |
| Support Level | $85.14 | $63.98 |
| Resistance Level | $102.25 | $100.28 |
| Average True Range (ATR) | 3.90 | 4.73 |
| MACD | 0.39 | 0.89 |
| Stochastic Oscillator | 10.71 | 47.83 |
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.